Irritable bowel syndrome is a common chronic gastrointestinal condition characterized by abdominal pain and bloating with altered bowel habits.
There are no identifiable physical, radiologic or lab abnormalities indicative of organic disease.
Symptoms may be exacerbated by stress, alcohol or food.
Treatment with tenapanor 50 mg twice daily (bid) results in improvement of constipation-predominant irritable bowel syndrome (IBS-C) symptoms and is generally well tolerated, a phase III study has shown.
An association appears to exist between irritable bowel syndrome (IBS) and small intestinal bacterial overgrowth (SIBO), suggest the results of a systematic review and meta-analysis. However, the overall quality of evidence is low.
Stool microbial diversity and composition appear to have a significant effect on daily extraintestinal symptoms, stool consistency and quality of life (QoL) in women with irritable bowel syndrome (IBS), a recent study has shown.
Peppermint oil, regardless of whether it is released in the small intestine or in the ileocolon, is ineffective for overall symptom relief in irritable bowel syndrome (IBS), a new study has found. In contrast, it shows significant efficacy for abdominal pain, discomfort and disease severity.
Faecal microbiota transplantation (FMT) is effective in reducing symptoms of irritable bowel syndrome (IBS), but having a “super-donor” is key, a study presented at UEG* Week has shown — highlighting the importance of donor selection for the success of FMT as a treatment for IBS.
Treatment with the combination of pinaverium bromide plus simethicone effectively relieves abdominal pain and bloating in patients with active irritable bowel syndrome (IBS), in addition to improving stool consistency in those with constipation-predominant IBS or a mixed bowel movement pattern, according to the results of a trial.
New drug application approved by US FDA as of 01 - 15 September 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Dr Andrew Ong, a consultant at the Department of Gastroenterology & Hepatology, Singapore General Hospital, explains to Roshini Claire Anthony the challenges in diagnosing and treating irritable bowel syndrome (IBS).
Cognitive behavioural therapy (CBT), delivered over the web or phone, yields superior improvements in irritable bowel syndrome (IBS) symptoms and more favourable effects on life and mood in comparison with treatment as usual, according to data from the ACTIB* trial.
Faecal bile acids and faecal fat predict clinically relevant diarrhoea and constipation in irritable bowel syndrome (IBS) patients who may require more specific treatment rather than simple symptom management, a study has found.
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.